Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM63NGW)

Drug Name

RS-100302 Drug Info

Synonyms

UNII-XX514BJ1XW; XX514BJ1XW; 120788-07-0; Sulopenem [USAN:INN]; AC1OCF0J; SCHEMBL73397; FLSUCZWOEMTFAQ-IIOOQZKLSA-N; (5R,6S)-6-((1R)-1-Hydroxyethyl)-7-oxo-3-(((3S)-tetrahydro-3-thienyl)thio)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, (R)-S-oxide; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-((tetrahydro-3-thie

Indication

Disease Entry	ICD 11	Status	REF
Atrial fibrillation	BC81.3	Investigative	[1]

Cross-matching ID

PubChem CID: 9805252
CAS Number: CAS 219757-90-1
TTD Drug ID: DM63NGW

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated potassium channel Kv1.5 (KCNA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[1]
BMS-919373	DMN28WK	Atrial fibrillation	BC81.3	Phase 2	[2]
IQB-9302	DMET0H4	Pain	MG30-MG3Z	Phase 1	[3]
XEN-D0103	DMR0U4V	Atrial fibrillation	BC81.3	Phase 1	[4]
BMS-394136	DMGDJQR	Arrhythmia	BC9Z	Phase 1	[5]
XEN-D0101	DMU0V45	Atrial fibrillation	BC81.3	Phase 1	[6]
T-226296	DMJ6P9U	Obesity	5B81	Preclinical	[1]
Zatebradine	DMNYKOT	Angina pectoris	BA40	Terminated	[7]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[8]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	DMKMH5L	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated potassium channel Kv1.5 (KCNA5)	TTW0CMT	KCNA5_HUMAN	Blocker	[1]

------------------------------------------------------------------------------------

References

1	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504)
3	Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
5	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6	Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15.
7	DOI: 10.1161/01.CIR.94.3.562
8	Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
9	Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92.